2361 - Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer with Liver Metastases: A Multicenter Retrospective Evaluation of Survival Outcomes
Presenter(s)
X. Fan1, B. Li1, C. Jiang2, Y. Wang1, T. Dong3, and L. Wang4; 1Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, 2Department of Otorhinolaryngology & Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China, 3Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, China, 4Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Jinan, Shandong, China
Purpose/Objective(s): While chemoimmunotherapy represents the cornerstone of first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC), the addition of thoracic radiotherapy (TRT) has been increasingly recognized for its potential to extend survival benefits. Liver metastases (LMs) were associated with poor outcomes in ES-SCLC patients. However, the specific role and potential benefits of TRT in ES-SCLC patients with LMs remain underexplored.
Materials/Methods: ES-SCLC patients received first-line chemoimmunotherapy were enrolled from four medical centers during January 2020 to January 2024. The baseline characteristics, treatment strategies and survival data were collected. Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan–Meier method and compared through log-rank tests.
Results: A total of 343 ES-SCLC patients receiving first-line chemotherapy and immunotherapy were retrospectively enrolled, and 89 (26.0%) had baseline LMs. Of these patients, 39 received chemoimmunotherapy combined with TRT. Survival analysis revealed significantly inferior PFS (mPFS: 6.8 vs. 9.3 months, p<0.001) and OS (mOS: 19.1 vs. 22.7 months, p<0.001) for patients with baseline LMs compared to those without LMs. Among patients with baseline LMs, no significant difference in PFS (mPFS: 8.0 vs. 6.0 months, p=0.114) and OS (mOS: 21.3 vs. 18.7 months, p=0.457) outcomes between the TRT and non-TRT subgroup was observed.
Conclusion: ES-SCLC patients diagnosed with baseline LMs had poor survival. The addition of TRT demonstrated no survival improvement for ES-SCLC patients with LMs receiving first-line chemoimmunotherapy. Considering the limits of a retrospective analysis, these preliminary results should be interpreted cautiously and should be further verified in future prospective trials.